Kyverna Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Kyverna Therapeutics, Inc. (KYTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $5.88 per share as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-08-11
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $5.88.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $5.43.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $4.77.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $4.81.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $5.88 10-Q · filed 2026-08-11 |
| 2026-03-31 | $5.43 10-Q · filed 2026-05-12 |
| 2025-12-31 | $4.77 10-Q · filed 2026-08-11 |
| 2025-09-30 | $4.81 10-Q · filed 2025-11-12 |
| 2025-06-30 | $4.74 10-Q · filed 2025-08-12 |
| 2025-03-31 | $5.60 10-Q · filed 2025-05-13 |
| 2024-12-31 | $5.83 10-K · filed 2026-03-26 |
| 2024-09-30 | $5.97 10-Q · filed 2024-11-13 |
| 2024-06-30 | $5.51 10-Q · filed 2024-08-12 |
| 2024-03-31 | $5.42 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.09 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |